PTC Therapeutics Posts $51.7M Q3 Loss
PTCT is trading near its 52-week low of $58.8 (9.8% above the low).
Summary
PTC Therapeutics reported a third-quarter loss of $51.7 million, or 62 cents a share, a swing to red ink after Q2 2026 net income of $83.5 million. The prior quarter was lifted by the Sephience launch and a $50 million milestone payment, so the loss raises the question of whether that revenue was one-time in nature. Third-quarter revenue came in at $357.8 million. The company carries a roughly $5.4 billion market value, so a quarterly loss of this size is meaningful but not existential. PTC raised its 2026 outlook to revenue of $1.29 billion to $1.32 billion, including full-year product revenue of $960 million to $990 million.
At the time of this announcement, PTCT was trading at $64.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $58.80 to $90.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.